BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
Instructions to Construct an Organization While Chasing after a Web-based Degree- The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- Everything to know about NASA's moon mission launching this week
- Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
- Artemis 2 breaks humanity's all-time distance record during historic loop around the moon (video)
- Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel
- IDF, police arrest eleven for criminal, terror-related activity over weekend
- NASA’s Pandora telescope will study stars in detail to learn about the exoplanets orbiting them
- Holocaust survivor, descendants urge High Court to allow Gaza children medical access
